0000905718-17-000323.txt : 20170302 0000905718-17-000323.hdr.sgml : 20170302 20170302161710 ACCESSION NUMBER: 0000905718-17-000323 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170302 DATE AS OF CHANGE: 20170302 EFFECTIVENESS DATE: 20170302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Variant Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001613083 IRS NUMBER: 465188564 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-281680 FILM NUMBER: 17659005 BUSINESS ADDRESS: STREET 1: 2200 N. COMMERCE PARKWAY STREET 2: SUITE 200 CITY: WESTON STATE: FL ZIP: 33326 BUSINESS PHONE: 954-931-2075 MAIL ADDRESS: STREET 1: 2200 N. COMMERCE PARKWAY STREET 2: SUITE 200 CITY: WESTON STATE: FL ZIP: 33326 D 1 primary_doc.xml X0707 D LIVE 0001613083 Variant Pharmaceuticals, Inc. 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 954-931-2075 FLORIDA None None Corporation true 2014 Stephen C Glover 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Executive Officer Director Shawn M Titcomb 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Director Nico Pronk 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Director Aaron Greenblatt 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Director Jules Musing 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Director Pharmaceuticals Decline to Disclose 06b false 2017-01-06 false true false 0 Noble Life Science Partners 15768 None None 225 N E MIZNER BLVD. BOCA RATON FL FLORIDA 33432 AK ALASKA AZ ARIZONA AR ARKANSAS CA CALIFORNIA CO COLORADO CT CONNECTICUT DE DELAWARE DC DISTRICT OF COLUMBIA FL FLORIDA GA GEORGIA HI HAWAII ID IDAHO IL ILLINOIS IN INDIANA IA IOWA KS KANSAS KY KENTUCKY LA LOUISIANA MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MS MISSISSIPPI NV NEVADA NH NEW HAMPSHIRE NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OH OHIO OK OKLAHOMA OR OREGON PA PENNSYLVANIA RI RHODE ISLAND SC SOUTH CAROLINA TN TENNESSEE TX TEXAS UT UTAH VA VIRGINIA WA WASHINGTON WV WEST VIRGINIA WI WISCONSIN WY WYOMING false 7000000 525000 6475000 false 7 490000 true 0 true Assumes maximum commissions earned. 0 true Some of the proceeds will be used for general working capital, which may include the payment of salaries and other fees to those listed in Item 3. Mr. Titcomb is a related party to, and Mr. Pronk holds a controlling interest in the Placement Agent. false Variant Pharmaceuticals, Inc. /s/ Stephen C. Glover Stephen C. Glover CEO 2017-03-02